Zydus Lifesciences bags USFDA approval for Pemetrexed for Injection; stock gains ~1%

26 May 2022 , 01:12 PM

Zydus Lifesciences Ltd. (formerly Cadila Healthcare) informed the investors and exchanges that the company has received final approval from the United States Food and Drug Administration (USFDA) to market Pemetrexed for Injection, available in 100 mg/vial,500 mg/vial, and 1000 mg/vial Single-Dose Vials.

Pemetrexed will facilitate in curing of certain types of cancers such as lung cancer, and mesothelioma. It is a chemotherapy drug that functions by slowing or stopping the growth of cancer cells. The drug will be manufactured at Zydus’ Hospira facility.

As per IQVIA MAT March’22 data, Pemetrexed for Injection has a market size of about USD 1,236 million.

The Zydus group now has a total of 314 approvals and has so far it has filed over 400 ANDAs since the commencement of its filing process in FY 2003-04.

At around 1.16 PM, Zydus Lifesciences was trading at Rs370.40 up by Rs4.15 or 1.13% from its previous closing of Rs366.25 on the BSE. The scrip opened at Rs368.95 and has touched intraday high and low of Rs371.10 and Rs363.80 respectively.